Should I buy or sell Prestige Consumer Healthcare stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PBH shares. View PBH analyst ratings or view top-rated stocks .

What is Prestige Consumer Healthcare's stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Prestige Consumer Healthcare's stock. Their PBH share price targets range from $103.00 to $117.00. On average, they predict the company's share price to reach $110.00 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View analysts price targets for PBH or view top-rated stocks among Wall Street analysts .

How have PBH shares performed in 2024?

Prestige Consumer Healthcare's stock was trading at $61.22 at the start of the year. Since then, PBH stock has increased by 13.8% and is now trading at $69.67. View the best growth stocks for 2024 here .

When is Prestige Consumer Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PBH earnings forecast .

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings data on Thursday, February, 8th. The company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.04 by $0.02. The business had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 14.09%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.04 earnings per share.

Is Prestige Consumer Healthcare a good dividend stock?

Prestige Consumer Healthcare (NYSE:PBH) pays an annual dividend of $1.90 per share and currently has a dividend yield of 0.00%.

What ETFs hold Prestige Consumer Healthcare's stock?

ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , Invesco S&P SmallCap Health Care ETF (PSCH) , Schwab Ariel ESG ETF (SAEF) , Global X Health & Wellness ETF (BFIT) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and iShares U.S. Pharmaceuticals ETF (IHE) .

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare issued an update on its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 4.330-4.330 for the period, compared to the consensus earnings per share estimate of 4.320. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com . Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE) , AbbVie (ABBV) , Gilead Sciences (GILD) , AT&T (T) , Intel (INTC) , ONEOK (OKE) , Wells Fargo & Company (WFC) , International Business Machines (IBM) , Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA) .

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.11%), Congress Asset Management Co. MA (1.54%), Congress Wealth Management LLC DE (0.25%), Norden Group LLC (0.24%), Olstein Capital Management L.P. (0.08%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi . View institutional ownership trends .

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PBH Stock Alerts

$69.67

+1.32 (+1.93%)

(As of 04/19/2024 ET)

Compare

Today's Range: $68.17
▼
$69.96
50-Day Range: $66.58
▼
$75.15
52-Week Range: $55.96
▼
$75.31

Volume: 454,206 shs
Average Volume: 239,816 shs
Market Capitalization: $3.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $110.00

Get Prestige Consumer Healthcare alerts:

Prestige Consumer Healthcare MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 57.9% Upside
$110.00 Price Target
Short Interest: Healthy
3.52% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$380,296 Sold Last Quarter
Proj. Earnings Growth: 6.47%
From $4.33 to $4.61 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

245th out of 911 stocks

Pharmaceutical Preparations Industry

98th out of 411 stocks

3.3

Analyst's Opinion

Consensus Rating
Prestige Consumer Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Prestige Consumer Healthcare has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.52% of the float of Prestige Consumer Healthcare has been sold short.
Short Interest Ratio / Days to Cover
Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Prestige Consumer Healthcare has recently decreased by 6.99%, indicating that investor sentiment is improving significantly.

0.8

Dividend Strength

Dividend Yield
Prestige Consumer Healthcare does not currently pay a dividend.
Dividend Growth
Prestige Consumer Healthcare does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Prestige Consumer Healthcare will have a dividend payout ratio of 41.21% next year. This indicates that Prestige Consumer Healthcare will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Prestige Consumer Healthcare has received a 42.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dental floss", "Topical capsaicin", "Mouthwash", "Lice shampoo", "Montelukast", and "Yeast infection medicine" products. See details.
Environmental Sustainability
The Environmental Impact score for Prestige Consumer Healthcare is -2.35.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for PBH on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Prestige Consumer Healthcare to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prestige Consumer Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $380,296.00 in company stock.
Percentage Held by Insiders
Only 1.60% of the stock of Prestige Consumer Healthcare is held by insiders.
Percentage Held by Institutions
99.95% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Prestige Consumer Healthcare are expected to grow by 6.47% in the coming year, from $4.33 to $4.61 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prestige Consumer Healthcare is -42.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prestige Consumer Healthcare is -42.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Prestige Consumer Healthcare has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Prestige Consumer Healthcare has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Prestige Consumer Healthcare Stock (NYSE:PBH)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PBH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PBH Stock News Headlines

April 3, 2024 | globenewswire.com

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag

March 23, 2024 | wsj.com

Prestige Consumer Healthcare Inc.

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 23, 2024 | finance.yahoo.com

Is Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 49% Discount?

March 15, 2024 | msn.com

Perrigo has no exposure to infant formula litigation, CG says

March 8, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL)

February 18, 2024 | finance.yahoo.com

PBH Mar 2024 55.000 put

February 18, 2024 | finance.yahoo.com

PBH Jul 2024 70.000 call

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 16, 2024 | finance.yahoo.com

Insider Sell: CFO Christine Sacco Sells 30,019 Shares of Prestige Consumer Healthcare Inc (PBH)

February 11, 2024 | finance.yahoo.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

February 9, 2024 | msn.com

Prestige Consumer Healthcare Begins Sharing Financial Results

February 9, 2024 | finance.yahoo.com

Prestige Consumer Healthcare Third Quarter 2024 Earnings: EPS Beats Expectations

February 8, 2024 | seekingalpha.com

Prestige Consumer Healthcare Inc. 2024 Q3 - Results - Earnings Call Presentation

February 8, 2024 | washingtonpost.com

Prestige Consumer Healthcare: Fiscal Q3 Earnings Snapshot

February 8, 2024 | msn.com

Prestige Consumer Healthcare (PBH) Surpasses Q3 Earnings and Revenue Estimates

February 8, 2024 | finance.yahoo.com

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results

February 8, 2024 | finance.yahoo.com

Prestige Consumer Healthcare Inc. (PBH) Reports Modest Revenue and EPS Growth in Q3 Fiscal 2024

February 7, 2024 | msn.com

Prestige Consumer Healthcare Q3 2024 Earnings Preview

February 2, 2024 | finance.yahoo.com

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

February 1, 2024 | finance.yahoo.com

Prestige Consumer Healthcare (PBH) Reports Next Week: What Awaits?

January 22, 2024 | finance.yahoo.com

Verano Holdings Corp. (VRNOF) Surges 6.5%: Is This an Indication of Further Gains?

January 10, 2024 | finance.yahoo.com

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results

December 22, 2023 | finance.yahoo.com

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene

November 29, 2023 | finance.yahoo.com

Should You Invest in Prestige Consumer Healthcare Inc. (PBH)?

November 29, 2023 | finance.yahoo.com

Should You Invest in Prestige Consumer Healthcare (PBH)?

November 24, 2023 | finance.yahoo.com

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene

See More Headlines

Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Current Symbol: NYSE:PBH
CUSIP: 74112D10
CIK: 1295947
Web: www.prestigebrands.com
Phone: (914) 524-6800
Fax: 302-674-5266
Employees: 560
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $110.00
High Stock Price Target: $117.00
Low Stock Price Target: $103.00
Potential Upside/Downside: +57.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 16.09
P/E Growth: 1.84
Net Income: $-82,310,000.00
Net Margins: -7.11%
Pretax Margin: -8.01%
Return on Equity: 14.09%
Return on Assets: 6.39%

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 3.09
Quick Ratio: 1.92

Sales & Book Value

Annual Sales: $1.13 billion
Price / Sales: 3.05
Cash Flow: $5.13 per share
Price / Cash Flow: 13.58
Book Value: $29.12 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 49,649,000
Free Float: 48,855,000
Market Cap: $3.46 billion
Optionable: Optionable
Beta: 0.52

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Ronald M. Lombardi (Age 60)
Chairman, President & CEO
Comp: $1.98M
Ms. Christine Sacco (Age 48)
Chief Financial Officer
Comp: $958.91k
Mr. Jeffrey Zerillo (Age 63)
Senior Vice President of Operations
Comp: $496.91k
Mr. William C. P'Pool (Age 59)
Senior VP, General Counsel & Corporate Secretary
Comp: $769.98k
Mr. Adel Mekhail (Age 63)
Executive Vice President of Marketing & Sales
Comp: $797.94k
Mr. Philip David Terpolilli
Director of Investor Relations
Dean Siegal
Director of Communications
Ms. Mary Beth Fritz
Senior Vice President of Quality & Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.
What is Prestige Consumer Healthcare's stock price target for 2024?: 2 Wall Street analysts have issued 1-year target prices for Prestige Consumer Healthcare's stock. Their PBH share price targets range from $103.00 to $117.00. On average, they predict the company's share price to reach $110.00 in the next year. This suggests a possible upside of 57.9% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.
How have PBH shares performed in 2024?: Prestige Consumer Healthcare's stock was trading at $61.22 at the start of the year. Since then, PBH stock has increased by 13.8% and is now trading at $69.67.
View the best growth stocks for 2024 here.
When is Prestige Consumer Healthcare's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBH earnings forecast.
How were Prestige Consumer Healthcare's earnings last quarter?: Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings data on Thursday, February, 8th. The company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.04 by $0.02. The business had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 14.09%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.04 earnings per share.
Is Prestige Consumer Healthcare a good dividend stock?: Prestige Consumer Healthcare (NYSE:PBH) pays an annual dividend of $1.90 per share and currently has a dividend yield of 0.00%.

What ETFs hold Prestige Consumer Healthcare's stock?: ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), Global X Health & Wellness ETF (BFIT), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and iShares U.S. Pharmaceuticals ETF (IHE).
What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?: Prestige Consumer Healthcare issued an update on its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 4.330-4.330 for the period, compared to the consensus earnings per share estimate of 4.320. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?: 8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Prestige Consumer Healthcare own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).
Who are Prestige Consumer Healthcare's major shareholders?: Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.11%), Congress Asset Management Co. MA (1.54%), Congress Wealth Management LLC DE (0.25%), Norden Group LLC (0.24%), Olstein Capital Management L.P. (0.08%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.
How do I buy shares of Prestige Consumer Healthcare?: Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PBH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial